证券代码：600329 证券简称：达仁堂 编号：临 2023-039 号 津药达仁堂集团股份有限公司 关于通过公开摘牌方式受让天津医药集团财务有限 公司 15%股权暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、竞拍结果 公司在财务公司股权（项目编号 G32023TJ1000066）挂牌公示期 间向天津产权交易中心（以下简称"天津产权"）提交了的意向受让 申请。近日，公司作为该项目挂牌期间唯一一家受让意向方，获得财 务公司 15%股权的最终受让方资格，受让价格为人民币 8,782.386 万 元，并已向天津产权指定账户支付保证金人民币 2,600 万元。 1 一、交易概述 公司于 2023 年 9 月 11 日召开 2023 年第六次董事会，会议审议 通过了"公司拟通过公开摘牌方式受让天津医药集团财务有限公司 15%股权暨关联交易的议案"，同意公司以公开摘牌方式参与竞拍天 津医药集团财务有限公司（以下简称"财务公司"或"标的企业"） 15%股权转让，摘牌报价为 8,782.386 万元人民币，资金来源 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-038 号 津药达仁堂集团股份有限公司 关于拟通过公开摘牌方式受让天津医药集团财务有限 公司 15%股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、关联交易概述 2023 年 8 月 28 日，天津产权交易中心发布公告，天津力生制药 股份有限公司所持有的天津医药集团财务有限公司（以下简称"财务 公司"）15%股权于 2023 年 8 月 28 日至 2023 年 9 月 22 日在天津 产权交易中心公开挂牌转让，挂牌转让底价为 8,782.386 万元人民币。 公司拟以公开摘牌方式参与竞拍本次股权转让，摘牌报价为8,782.386 万元人民币，交易金额占公司最近一期经审计归母净资产的 1.35%， 资金来源为公司自有资金。若发生竞价，具体交易金额将以竞价结果 1 本公司拟通过公开摘牌方式受让天津医药集团财务有限公司 15%股权， 摘牌报价为 8,782.386 万元人民币。 本次交易构成关联交易。郭珉、张铭芮、毛蔚雯作为关联 ...

津药达仁堂集团股份有限公司 独立董事关于公司2023年第六次董事会相关事项的 独立意见 根据中国证监会《关于在上市公司建立独立董事制度的指导意 见》、《上市公司治理准则》，上海证券交易所《股票上市规则》、 本公司《公司章程》与《独立董事制度》等有关规定，我们作为津药 达仁堂集团股份有限公司（以下简称"本公司"或"公司"）的独立 董事，对公司2023年第六次董事会审议的相关事项进行了核查，现对 有关事项发表独立意见如下： 独立董事： 刘育彬 李 清 朱海峰 2023 年 9 月 11 日 一、关于公司拟通过公开摘牌方式受让天津医药集团财务有限公 司15%股权的事项。 公司本次董事会的召开、表决程序符合相关法律、法规及《公司 章程》的规定，关联董事回避了表决。公司拟通过公开摘牌方式受让 天津医药集团财务有限公司15%股权，均遵循平等自愿、互利互惠的 原则，该交易未影响本公司的独立性，没有损害上市公司及中小股东 的利益。本项关联交易的协议内容合法、有效，不存在违反现行有效 的法律、法规和规范性文件强制性规定的情形。 ...

津药达仁堂集团股份有限公司 关于公司 2023 年第六次董事会相关事项的 独立董事事前认可意见 津药达仁堂集团股份有限公司（以下简称"公司"）将于 2023 年 9 月 11 日以现场结合通讯方式召开 2023 年第六次董事会会议。会 议将审议"公司拟通过公开摘牌方式受让天津医药集团财务有限公司 15%股权暨关联交易的议案"。 2．公司拟通过公开摘牌方式受让天津医药集团财务有限公司 15%股权，均遵循平等自愿、互利互惠的原则，未影响本公司的独立 性，没有损害上市公司及中小股东的利益。 3．上述事项的协议内容合法、有效，不存在违反现行有效的法 律、法规和规范性文件强制性规定的情形。 4．我们同意将该事项提交公司 2023 第六次董事会审议。 独立董事： 刘育彬 李 清 朱海峰 2023 年 9 月 11 日 根据中国证监会《关于在上市公司建立独立董事制度的指导意 见》、《上市公司治理准则》，上海证券交易所《股票上市规则》和新 加坡交易所有关规则、本公司《公司章程》与《独立董事制度》等相 关规定，作为公司独立董事，我们在事前对本次事项进行认真研究， 基于独立判断的立场，发表如下意见： 1．公司控股股东天津市医药集 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司于 2023 年 9 月 1 日发出会议通知， 并于 2023 年 9 月 11 日以现场结合通讯方式召开了 2023 年第六次董 事会会议。本次会议应参加董事 9 人，实参加董事 9 人。会议召开符 合《公司法》、《证券法》和《公司章程》有关召开董事会会议的规定。 会议形成如下决议： 一、审议通过了公司拟通过公开摘牌方式受让天津医药集团财务 有限公司 15%股权暨关联交易的议案。（详见临时公告 2023-038 号） 证券代码：600329 证券简称：达仁堂 编号：临 2023-037 号 津药达仁堂集团股份有限公司 2023 年第六次董事会决议公告 1 及符合香港联合交易所有限公司证券上市规则（简称"上市规则"） 的规定（包括：根据上市规则取得天津发展股东于股东大会中批准本 合同及其项下交易(如适用)）后，方可履行。 公司董事郭珉、张铭芮、毛蔚雯作为关联董事，回避表决此议案。 公司独立董事刘育彬、李清、朱海峰对本议案发表了独立意见。 表决结果：同意 ...

证券代码:600329 证券简称:达仁堂 津药达仁堂集团股份有限公司 投资者调研接待记录 调研方式:线上联合调研 调研时间 2023 年 9 月 1 日 15:30—16:53 公司接待人员 董 事 长:张铭芮 董事、总经理:王 磊 首席财务 官:马 健 董事会秘 书:焦 艳 与会投资者 中邮证券 国融基金 尚诚资产 淳厚基金 华安证券 兴合基金 循远资产 天猊投资 安信证券 宝盈基金 沣谊投资 凯思博投资 国海证券 博道基金 弢盛资产 汇百川基金 国融证券 上银基金 鸿涵投资 逸原达投资 浙商证券 国泰基金 长谋投资 金之灏基金 财通证券 中加基金 贵源投资 优益增投资 渤海证券 财通基金 致顺投资 新同方投资 开源证券 富国基金 奥昇投资 红思客资产 民生证券 中融基金 火星资产 复兴城投资 华创证券 兴业基金 双诚资产 源乐晟资管 东亚前海 长盛基金 青榕资产 金百镕投资 西部证券 博道基金 沣杨资产 康曼德资本 华泰证券 中金基金 知远投资 仙人掌私募 中天国富 华宝基金 青骊投资 金光紫金创投 国联证券 国君资管 坚果投资 海创百川私募 西南证券 农银人寿 健顺投资 交辉创业投资 五矿证券 中欧基金 ...

证券代码：600329 证券简称：达仁堂 编号：临 2023-036 号 津药达仁堂集团股份有限公司 关于召开 2023 年半年报业绩说明会暨参加天津辖区 上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 5 日（星期二）下午 15:00—16:40 会议召开地点：全景路演（http: //rs.p5w.net） 会议召开方式：网络互动 投资者可于 2023 年 9 月 1 日（星期五）17:00 前预先提出所 关 注 的 问 题 并 以 电 子 邮 件 方 式 发 送 到 公 司 邮 箱 （drt600329@163.com）。公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 津药达仁堂集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 15 日发布了 2023 年半年度报告（详见上海证券交易所网站 www.sse.com.cn）。为便于广大投资者更深入全面地了解公司经营业 绩等情况，公司定于 2023 年 ...

关于召开 2023 年半年报业绩说明会暨参加天津辖区 上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 证券代码：600329 证券简称：达仁堂 编号：临 2023-036 号 津药达仁堂集团股份有限公司 召开时间：2023 年 9 月 5 日（星期二）下午 15:00—16:40 召开地点：全景路演（http: //rs.p5w.net） 1 会议召开时间：2023 年 9 月 5 日（星期二）下午 15:00—16:40 会议召开地点：全景路演（http: //rs.p5w.net） 会议召开方式：网络互动 投资者可于 2023 年 9 月 1 日（星期五）17:00 前预先提出所 关 注 的 问 题 并 以 电 子 邮 件 方 式 发 送 到 公 司 邮 箱 （drt600329@163.com）。公司将在说明会上对投资者普遍关 注的问题进行回答。 召开方式：网络互动 三、参加人员 出席本次说明会的人员有：董事长张铭芮女士、总经理王磊女士、 独立董事代 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 4,088,308,842.02, an increase of 8.31% compared to the same period last year[16] - Net profit attributable to shareholders of the listed company was RMB 722,491,488.60, a significant increase of 54.12% year-on-year[16] - Basic earnings per share (EPS) for the reporting period were RMB 0.94, up 54.10% compared to the same period last year[17] - Weighted average return on equity (ROE) increased by 3.22 percentage points to 10.54%[17] - Operating cash flow increased by 37.48% to RMB 122,433,735.29[16] - Revenue increased by 8.31% to 4,088,308,842.02 yuan compared to the same period last year[61] - Net profit attributable to shareholders of the parent company was 722 million yuan, a significant increase of 54.12% year-on-year[36] - Operating revenue for the first half of 2023 reached 4,088,308,842.02 RMB, up from 3,774,763,809.73 RMB in the same period last year[144] - Net profit attributable to parent company shareholders reached 722,491,488.60 RMB, compared to 468,785,051.09 RMB in the same period last year[146] - Basic earnings per share (EPS) rose to 0.94 RMB from 0.61 RMB in the previous year[147] - Total comprehensive income reached 715,838,377.52 RMB, up from 476,925,168.97 RMB in the same period last year[147] - Sales revenue from goods and services increased to 4,159,478,789.36 in H1 2023, up from 3,438,491,278.73 in H1 2022, reflecting a 20.96% growth[152] - Net cash flow from operating activities rose to 122,433,735.29 in H1 2023, compared to 89,054,915.47 in H1 2022, indicating a 37.47% increase[152] - Comprehensive income for the period was RMB 715.8 million, driven by a net profit of RMB 722.5 million[158] - Total comprehensive income for the period was RMB 81.7 million, with a net profit contribution of RMB 85.1 million[160] - The comprehensive income for the period was RMB 757,671,375.90, driven by a net profit of RMB 756,300,446.31[162] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 10,364,005,536.89, an increase of 2.04% compared to the end of the previous year[16] - Net assets attributable to shareholders of the listed company decreased by 2.90% to RMB 6,332,314,528.74[16] - Total assets increased to 10,364,005,536.89 RMB as of June 30, 2023, compared to 10,156,982,039.41 RMB at the end of 2022[138][139][140] - Cash and cash equivalents decreased to 2,103,958,426.22 RMB from 2,882,523,954.61 RMB, a decline of 27%[138] - Accounts receivable increased by 17.2% to 2,515,042,678.31 RMB from 2,146,213,416.31 RMB[138] - Inventory rose by 17.4% to 1,677,798,658.15 RMB from 1,429,451,795.45 RMB[138] - Short-term borrowings surged by 421.6% to 530,169,300.45 RMB from 101,638,515.28 RMB[139] - Total liabilities increased to 3,974,356,989.02 RMB, up 10.2% from 3,605,028,900.58 RMB[139][140] - Shareholders' equity decreased by 2.5% to 6,389,648,547.87 RMB from 6,551,953,138.83 RMB[140] - Long-term investments grew by 11.8% to 849,612,344.04 RMB from 760,192,827.41 RMB[138] - Fixed assets declined by 3.8% to 1,084,531,897.41 RMB from 1,127,742,589.56 RMB[138] - Intangible assets increased by 17.3% to 329,797,889.45 RMB from 281,127,790.71 RMB[139] - Total assets increased to 8,998,033,329.54 RMB, up from 8,901,211,797.61 RMB in the previous period[142] - Long-term equity investments rose to 2,349,217,735.84 RMB, compared to 2,296,458,142.20 RMB previously[142] - Total liabilities increased to 2,314,470,286.33 RMB, up from 2,094,478,021.81 RMB previously[143] - Shareholders' equity decreased to 6,683,563,043.21 RMB, down from 6,806,733,775.80 RMB in the previous period[143] - Total owner's equity at the end of the period decreased by RMB 162.3 million to RMB 6.39 billion, compared to the beginning of the period[158][159] - Owner's equity decreased by RMB 189.1 million due to a reduction in capital and retained earnings[158] - Capital reserve decreased by RMB 72.7 million, primarily due to share-based payments and other adjustments[158] - Retained earnings at the end of the period stood at RMB 4.13 billion, down from RMB 4.26 billion at the beginning[158] - The company's total owner's equity at the end of the period was RMB 6,595,494,148.73, with a net increase of RMB 144,131,574.66 compared to the previous period[161] - The company's total owner's equity at the beginning of the period was RMB 6,806,733,775.80, with a decrease of RMB 123,170,732.59 during the period[162] - The company's total owner's equity at the end of the period was RMB 6,683,563,043.21, reflecting a decrease from the beginning balance[163] - The company's capital reserve increased by RMB 3,576,387.27 due to owner contributions and reductions in capital[165] - The company's total owner's equity at the end of the period was RMB 6,499,139,607.20, reflecting a decrease from the beginning balance[165] Cash Flow - Operating cash flow increased by 37.48% to RMB 122,433,735.29[16] - Investment cash flow decreased by 193.63% to -487,182,638.67 RMB, mainly due to reduced cash receipts from investments[61] - Net cash flow from operating activities rose to 122,433,735.29 in H1 2023, compared to 89,054,915.47 in H1 2022, indicating a 37.47% increase[152] - Cash outflow for investments surged to 645,100,234.89 in H1 2023, up from 133,395,927.14 in H1 2022, a significant 383.60% rise[153] - Net cash flow from financing activities improved to -344,434,848.42 in H1 2023, from -381,537,177.75 in H1 2022, showing a 9.73% reduction in negative cash flow[153] - Cash and cash equivalents at the end of the period decreased to 2,001,527,474.76 in H1 2023, down from 2,511,049,911.58 in H1 2022, a 20.29% decline[153] - Parent company's net cash flow from operating activities fell to 305,253,953.34 in H1 2023, from 1,092,761,924.19 in H1 2022, a 72.07% decline[156] - Parent company's cash outflow for investments increased to 1,597,735,245.83 in H1 2023, up from 1,310,580,368.13 in H1 2022, a 21.91% rise[156] - Parent company's net cash flow from financing activities worsened to -697,139,366.90 in H1 2023, from -363,706,187.30 in H1 2022, a 91.68% increase in negative cash flow[157] - Parent company's cash and cash equivalents at the end of the period decreased to 1,682,541,310.01 in H1 2023, down from 2,087,439,919.72 in H1 2022, a 19.40% decline[157] Business Operations - The company's pharmaceutical manufacturing sector includes well-known products such as Su Xiao Jiuxin Wan and Jing Wan Hong Ointment, with a focus on traditional Chinese medicine[23] - The pharmaceutical commercial sector covers Tianjin and extends nationwide, with Tianjin Zhongxin Pharmaceutical Co., Ltd. being a leading drug distributor in Tianjin[24] - The company's procurement model involves electronic systems for supplier selection and has established GAP planting bases for herbs like Chuanxiong and Honeysuckle[25] - Production follows a "sales-driven" model with a 90-day rolling demand approval process to ensure supply and reasonable inventory[26] - Sales strategies include partnerships with leading commercial enterprises and a focus on academic and professional promotion, with efforts to expand online sales through B2B, B2C, and O2O models[27] - The company expanded its digital presence by deploying AI technologies like AIGC and ChatGPT across platforms such as Ali, JD, and TikTok[50] - 27 key research projects were focused on core products like Suxiao Jiuxin Pill and Qingyan Drop Pill, collaborating with institutions like the University of Macau and Tianjin University of Traditional Chinese Medicine[52] - The company completed the preparation of 4 health wine samples and advanced several health projects to the prescription confirmation and sample preparation stages[53] - A digital strategy for 2023-2027 was initiated, with the first phase of the IT strategy focusing on business unit empowerment[55] - The company expanded its team by over 200 employees, with a focus on frontline positions and optimizing performance management[59] - The company's "Qingyan Dripping Pills" were listed in 24 provinces and distributed to over 400 chain stores, with development in more than 2,000 medical terminals[43] - The company's "Suxiao Jiuxin Pill" was included in the "Chinese Guidelines for the Management of Hypertension in the Elderly"[45] - The company's "Tongmai Yangxin Pill" was included in the "Expert Consensus on Drug Therapy Management Pathways for Patients with Coronary Atherosclerotic Heart Disease"[45] - The company's "Bianqi Capsule" was included in the "Chinese Expert Guidelines for Non-Opioid Analgesic Drug Treatment of Chronic Musculoskeletal Pain"[45] Industry and Market Conditions - In 2023 H1, China's pharmaceutical manufacturing industry saw a 2.9% decrease in revenue to RMB 12,496.0 billion and a 17.1% drop in profit to RMB 1,794.5 billion[28] - National policies strongly support the development of traditional Chinese medicine, emphasizing its role in disease prevention, treatment, and rehabilitation[29] - Rising costs of traditional Chinese medicine materials and energy have increased pressure on cost control, with the China Traditional Chinese Medicine Price Index rising from 1738.89 in June 2022 to 2144.72 in June 2023[30] - The average price reduction in the second batch of centralized procurement for traditional Chinese medicine was 49.36%, significantly impacting pharmaceutical companies' pricing power[31] - The average price reduction in the second batch of centralized procurement of traditional Chinese medicines in Hubei was 49.36%, reflecting the increasing uncertainty for pharmaceutical companies due to the normalization of centralized procurement policies[75] - The price of traditional Chinese medicinal materials has increased significantly, rising from 1738.89 points in June 2022 to 2144.72 points in June 2023, reflecting a 23.3% year-over-year increase[77] - The company faces potential risks of rising labor costs due to increased employee compensation and social security levels[78] - The pharmaceutical market may experience limited growth in bid prices due to increased buyer bargaining power, particularly from medical insurance payments[79] - The pharmaceutical industry is facing intensified competition in retail channels, with a clearer path towards the separation of medical and pharmaceutical services[80] - New drug development is characterized by high investment, long cycles, and significant risks, with increasing technical review standards and potential delays or failures in market entry[81] - Regulatory requirements for drug quality and safety have been strengthened, with stricter standards for traditional Chinese medicine materials and higher expectations for drug vigilance[83] Corporate Governance and Shareholder Information - The company's A-share stock code is 600329, listed on the Shanghai Stock Exchange, and its S-share stock code is T14, listed on the Singapore Exchange[15] - The company has undergone several changes in its board and executive team, including the resignation of key personnel and the appointment of a new CFO[86] - No profit distribution or capital reserve conversion plan was proposed for the first half of the year[87] - The company has implemented a 2019 A-share restricted stock incentive plan, with multiple adjustments and cancellations of restricted stocks for non-compliant incentive objects[88][89] - The company's controlling shareholder, Tianjin Pharmaceutical Group, has committed to avoiding competition with the company and ensuring fair market principles in related transactions[99] - Tianjin Pharmaceutical Group commits to transferring over 50% equity of its pharmaceutical commercial business to an independent third party or injecting related businesses into the listed company platform by December 31, 2024, to resolve potential competition issues[101] - Tianjin Pharmaceutical Group will ensure compliance with state-owned asset management regulations and obtain necessary approvals from the Tianjin State-owned Assets Supervision and Administration Commission to resolve potential competition issues[101] - Tianjin Pharmaceutical Group promises to compensate the company for any losses incurred due to the Jinyao Amino Acid litigation[103] - Tianjin Bohai State-owned Assets Management Company commits to avoiding related-party transactions with the company and ensuring fair and reasonable transaction prices if unavoidable[102] - Tianjin Bohai State-owned Assets Management Company pledges to reduce and avoid competition by not engaging in or supporting businesses that compete with the company's main operations[102] - The company appointed Zhong Shen Hua Certified Public Accountants as its domestic auditor and FKT Certified Public Accountants as its overseas auditor for 2023, pending shareholder approval[104] - Total related-party transactions amounted to RMB 267.95 million, accounting for 9.755% of total transactions[108] - The largest related-party transaction was with Jinping Pharmaceutical Co., Ltd., amounting to RMB 93.89 million, accounting for 4.238% of similar transactions[105] - Sales to related parties totaled RMB 70.89 million, representing 1.734% of total sales[107] - The company engaged in significant transactions with its parent company's subsidiaries, including Jinping Pharmaceutical Co., Ltd. and Tianjin Hongrentang Pharmaceutical Co., Ltd.[105][107] - The company's transactions with its parent company's subsidiaries were primarily for the purchase and sale of goods, with pricing based on market rates[105][107] - The company's related-party transactions were predominantly settled in cash[105][107] - The company did not report any significant asset acquisitions, equity acquisitions, or sales during the reporting period[108] - No significant changes or progress were reported in previously disclosed joint investment-related transactions[109] - The company renewed the "Financial Services Agreement" with Tianjin Pharmaceutical Group Finance Co., Ltd., a related transaction that has been disclosed in temporary announcements since 2017[110] - The company's initial balance with Chengdu Zhongxin Pharmaceutical Co., Ltd. was 3,697,782.00 RMB, with no changes during the period, maintaining the same ending balance[111] - Tianjin Hongrentang Pharmaceutical Co., Ltd. had an initial balance of 1,059,900.00 RMB, which was fully reduced during the period, resulting in an ending balance of 0[111] - Tianjin Taiping Zhenhua Pharmacy Co., Ltd. had an initial balance of 66,690.00 RMB, which was fully reduced during the period, resulting in an ending balance of 0[112] - Tianjin Taiping Xiangyun Pharmaceutical Co., Ltd. had an initial balance of 642,988.64 RMB, with an increase of 5,473,315.62 RMB during the period, resulting in an ending balance of 6,116,304.26 RMB[112] - Tianjin Pharmaceutical Group Zhongjiankangda Medical Technology Co., Ltd. had an initial balance of 16,067.20 RMB, with no changes during the period, maintaining the same ending balance[112] - Victorch Meditek, Inc. had an initial balance of 589,483.54 RMB, with an increase of 9,969.54 RMB during the period, resulting in an ending balance of 599,453.08 RMB[112] - The company's deposit business with Tianjin Pharmaceutical Group Finance Co., Ltd. had an initial balance of 590,758,195.72 RMB, with total deposits of 18,820,869,644.39 RMB and total withdrawals of 18,822,861,635.55 RMB, resulting in an ending balance of 588,766,204.56 RMB[115] - The deposit interest rate range for the company's deposit business with Tianjin Pharmaceutical Group Finance Co., Ltd. was between 0.42% and 2.25%[115] - Loan business with Tianjin Pharmaceutical Group Finance Co., Ltd. (a related party) had a loan amount of 600,000,000 RMB, with an interest rate range of 3.68%-3.75%, and an ending balance of 327,890,000 RMB[116] - Total loan issuance during the period was 300,000,000 RMB, with repayments of 10,330,495.28 RMB, resulting in an ending balance of 327,890,000 RMB[116] - The company's total guarantee amount (including guarantees for subsidiaries) was 299,453,458.70 RMB, accounting for 4.73% of the company's net assets[121] - The company's total guarantee amount

关于津药达仁堂集团股份有限公司 继续使用部分闲置募集资金暂时补充流动资金的核查 意见 中国银河证券股份有限公司(以下简称"银河证券"或"保荐机构")作为 津药达仁堂集团股份有限公司¹(以下简称"达仁堂"或"公司")2015 年非公开发 行 A 股股票的保荐机构,根据《证券发行上市保荐业务管理办法》、《上市公司 监管指引第2号 -- 上市公司募集资金管理和使用的监管要求》、《上海证券交 易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 11 号——持 续督导》、《上海证券交易所上市公司自律监管指引第 1 号 -- 规范运作》等有 关规定，对达仁堂使用部分闲置募集资金暂时补充流动资金的情况进行了认真、 审慎的核查,具体核查情况如下: 一、募集资金基本情况 根据中国证券监督管理委员会"证监许可[2015]1072 号"《关于核准天津中 新药业集团股份有限公司非公开发行股票的批复》,达仁堂获准非公开发行不超 过人民币普通股(A 股)65,166,000 股。实际非公开发行人民币普通股(A 股)29,564,356 股，每股发行价格为人民币 28.28 元,股款以人民币缴足,共计人 民币 836,079,98 ...